Ticker Report Vaughan David Investments LLC IL trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 46.2% during the second quarter, according to the company in its most recent 13F filing with...\n more…
Investopedia Headlines Scott Olson / Getty Images\n\n Key TakeawaysEli Lilly is investing $1.8 billion to expand production in Ireland of its Alzheimer's treatment and weight-loss drugs.The company's Alzheimer's...\n more…
Benzinga Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.\n more…
Zacks Investment Research Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting.CT-996 is an investigational...\n more…
Ticker Report Quest Partners LLC lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.0% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 815 shares of...\n more…
Yahoo! Finance: News Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now...\n more…